

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

Art Unit: 1616

Kowalski, James et al.

Examiner: Yu, Hong

INTERNATIONAL APPLICATION NO: PCT/EP2005/000400

FILED: January 17, 2005

U.S. APPLICATION NO: 10/586059

35 USC §371 DATE: May 08, 2007

FOR: Direct Compression Formulation and Process

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT


Sir:

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Novartis Pharmaceuticals Corporation
One Health Plaza, Bldg. 101
East Hanover, NJ 07936
(862) 778-9499

Respectfully submitted,



Joseph Majka
Attorney for Applicant
Reg. No. 30,570

Date: September 13, 2010

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

Art Unit: 1616

Kowalski, James et al.

Examiner: Yu, Hong

INTERNATIONAL APPLICATION NO: PCT/EP2005/000400

FILED: January 17, 2005

U.S. APPLICATION NO: 10/586059

35 USC §371 DATE: May 08, 2007

FOR: Direct Compression Formulation and Process

MS: Amendment

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed:

- ☐ supplemental to the Information Disclosure Statement filed .
- ☐ within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 of the international application. Therefore, no fees are required.
- ☐ before the mailing date of a first Office action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required.

If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134 in the name of Novartis.

- ☒ This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c) or 37 C.F.R. §1.97(d).
- ☒ A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.


☒ Copies of the non-asterisked references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Novartis Pharmaceuticals Corporation
One Health Plaza, Bldg. 101
East Hanover, NJ 07936
(862) 778-9499

Date: September 13, 2010

Respectfully submitted,



Joseph Majka
Attorney for Applicant
Reg. No. 30,570